Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANGH | Anghami | $2.78 | $0.37 | 1330.93% | 2.1K | $19M | $2.25$7.70 |
| MOVE | Movano | $17.53 | $10.56 | 151.58% | 28.3M | $6.3M | $4.67$55.00 |
| BNAI | Brand Engagement Network | $12.33 | $3.67 | 42.32% | 4.1M | $39M | $1.18$13.04 |
| RVYL | Ryvyl | $7.45 | $2.21 | 42.18% | 10.3M | $5.4M | $4.50$81.55 |
| CHRS | Coherus Oncology | $2.02 | $0.43 | 27.04% | 5.1M | $192M | $0.71$2.03 |
| LIF | Life360 | $69.11 | $14.30 | 26.09% | 1.2M | $4.3B | $29.62$112.54 |
| UONE | Urban One | $11.43 | $2.13 | 22.86% | 19K | $418M | $8.60$19.00 |
| MAXN | Maxeon Solar Technologies | $3.52 | $0.56 | 18.92% | 791K | $50M | $2.49$6.58 |
| BGL | Blue Gold | $4.95 | $0.69 | 16.20% | 227.7K | $140M | $1.83$166.50 |
| ALT | Altimmune | $6.25 | $0.87 | 16.17% | 3.7M | $561M | $2.90$7.73 |
Related Articles
Featured Article
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Adam Spatacco|Aug 9, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Alex Carchidi|Jul 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Alex Carchidi|Jul 10, 2024
Both competitors have promising lead programs, and enough cash, too.
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alex Carchidi|Jun 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Alex Carchidi|Jun 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
1 Huge Reason Solar Stocks Are Poised for a Comeback
Travis Hoium|May 1, 2024
Solar panel prices are falling and that could be good for some solar energy stocks.
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
Alex Carchidi|Jun 16, 2023
Coherus' biosimilar to Humira could catapult the company to success.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
Keith Speights|Mar 22, 2023
It's not the end of the story for this once high-flying biotech stock.
My 3 Top Biotech Stock Picks for 2023
George Budwell, PhD|Nov 22, 2022
Biotech stocks are set to shine in 2023.
This Under-the-Radar Solar Stock Is Growing Fast
Rekah Khandelwal|May 3, 2022
The company's solar module shipments rose 76% year over year in the first quarter.
